---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034427"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:15:43.255279+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology reports FY2023 net loss of $73.8M, advances PYX-201 and PYX-106 trials

## Summary
- Net loss of $73.8M ($1.85/share) vs $120.7M ($3.65/share) in FY2022; R&D expenses fell to $49.6M from $86.1M.
- Cash, equivalents, and short-term investments $120.8M as of Dec 31, 2023; post-period raised $50M PIPE and $10.8M ATM, extending runway into 2H 2026.
- PYX-201 Phase 1: 37 patients dosed; cleared DLT for Cohort 6; escalating to Cohort 7 at 8 mg/kg; initial data expected fall 2024.
- PYX-106 Phase 1: 21 patients dosed; Cohort 5 fully enrolled at 8 mg/kg Q2W; preliminary data expected 2H 2024.
- Feb 2024 PIPE investors include Deep Track Capital, Ridgeback, Blue Owl, Laurion Capital, StemPoint Capital.

## SEC filing metadata
- accession: 0000950170-24-034427
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034427/0000950170-24-034427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034427/pyxs-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034427
- JSON: https://secwatch.observer/filing/0000950170-24-034427.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034427.txt

## Key facts
- Earnings Releases
  Pyxis Oncology, Inc. reported the full year ended December 31, 2023 results: net income $73.8 million, or ($1.85) per common share.
  - Period: the full year ended December 31, 2023
  - Net income: $73.8 million, or ($1.85) per common share
  - Result: reported results
  source text: Net loss was $73.8 million, or ($1.85) per common share, for the year ended December 31, 2023, compared to $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017024034427/0000950170-24-034427-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.